Header Logo

Connection

Vincent Tam to Anti-Bacterial Agents

Back to Details
This is a "connection" page, showing publications Vincent Tam has written about Anti-Bacterial Agents.
Vincent Tam
Connection Strength
22.269
Anti-Bacterial Agents
  1. Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A?case report. Pharmacotherapy. 2025 Jan; 45(1):66-69.
    View in: PubMed
    Score: 0.785
  2. In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
    View in: PubMed
    Score: 0.763
  3. Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury. Am J Physiol Renal Physiol. 2024 Jul 01; 327(1):F137-F145.
    View in: PubMed
    Score: 0.756
  4. Alternative iron-depleted media for cefiderocol susceptibility testing. Int J Antimicrob Agents. 2024 Jul; 64(1):107193.
    View in: PubMed
    Score: 0.754
  5. Comparison of cefiderocol in-vitro susceptibility testing modalities. J Glob Antimicrob Resist. 2024 Jun; 37:100-101.
    View in: PubMed
    Score: 0.748
  6. An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Am J Health Syst Pharm. 2022 03 07; 79(6):467-471.
    View in: PubMed
    Score: 0.649
  7. Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.
    View in: PubMed
    Score: 0.605
  8. Validation of Vancomycin Dosing Guidance During Transition of Care. J Clin Pharmacol. 2021 06; 61(6):806-809.
    View in: PubMed
    Score: 0.596
  9. A robust LC-MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies. Bioanalysis. 2020 Apr; 12(7):445-454.
    View in: PubMed
    Score: 0.570
  10. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 02 21; 64(3).
    View in: PubMed
    Score: 0.563
  11. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2).
    View in: PubMed
    Score: 0.523
  12. Toxicity in Patients. Adv Exp Med Biol. 2019; 1145:289-304.
    View in: PubMed
    Score: 0.520
  13. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348.
    View in: PubMed
    Score: 0.515
  14. Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol. 2018 Apr; 62(4):291-294.
    View in: PubMed
    Score: 0.493
  15. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538.
    View in: PubMed
    Score: 0.486
  16. The complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 06 01; 72(6):1632-1634.
    View in: PubMed
    Score: 0.466
  17. Determining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 05 01; 72(5):1421-1428.
    View in: PubMed
    Score: 0.463
  18. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5).
    View in: PubMed
    Score: 0.463
  19. Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 04; 61(4).
    View in: PubMed
    Score: 0.460
  20. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1).
    View in: PubMed
    Score: 0.453
  21. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982.
    View in: PubMed
    Score: 0.447
  22. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587.
    View in: PubMed
    Score: 0.442
  23. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5.
    View in: PubMed
    Score: 0.398
  24. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7.
    View in: PubMed
    Score: 0.397
  25. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.
    View in: PubMed
    Score: 0.396
  26. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1370.
    View in: PubMed
    Score: 0.391
  27. Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?". Antimicrob Agents Chemother. 2014 Oct; 58(10):6339.
    View in: PubMed
    Score: 0.388
  28. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8.
    View in: PubMed
    Score: 0.384
  29. Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014 Sep; 58(9):5239-44.
    View in: PubMed
    Score: 0.380
  30. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21.
    View in: PubMed
    Score: 0.377
  31. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014 Jul; 58(7):4200-2.
    View in: PubMed
    Score: 0.375
  32. Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents. 2014 Feb; 43(2):197-9.
    View in: PubMed
    Score: 0.364
  33. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64.
    View in: PubMed
    Score: 0.359
  34. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May; 68(5):1104-10.
    View in: PubMed
    Score: 0.345
  35. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2013 Mar; 57(3):1270-4.
    View in: PubMed
    Score: 0.343
  36. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis. 2013 Mar 01; 207(5):786-93.
    View in: PubMed
    Score: 0.342
  37. In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. Antimicrob Agents Chemother. 2013 Feb; 57(2):1062-4.
    View in: PubMed
    Score: 0.342
  38. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother. 2012 Nov; 56(11):5724-7.
    View in: PubMed
    Score: 0.335
  39. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9.
    View in: PubMed
    Score: 0.330
  40. In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7.
    View in: PubMed
    Score: 0.327
  41. Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 11 06; 68(11):e0089824.
    View in: PubMed
    Score: 0.194
  42. Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441.
    View in: PubMed
    Score: 0.181
  43. Growth of Acinetobacter baumannii impacted by iron chelation. Lett Appl Microbiol. 2023 Feb 16; 76(2).
    View in: PubMed
    Score: 0.173
  44. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927.
    View in: PubMed
    Score: 0.171
  45. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
    View in: PubMed
    Score: 0.170
  46. Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. J Chemother. 2022 09; 34(5):345-346.
    View in: PubMed
    Score: 0.159
  47. Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.
    View in: PubMed
    Score: 0.149
  48. MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates. J Glob Antimicrob Resist. 2020 12; 23:385-387.
    View in: PubMed
    Score: 0.148
  49. Prolonged Versus Intermittent Infusion of ?-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clin Pharmacokinet. 2020 10; 59(10):1237-1250.
    View in: PubMed
    Score: 0.147
  50. Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 08 20; 64(9).
    View in: PubMed
    Score: 0.146
  51. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254.
    View in: PubMed
    Score: 0.138
  52. Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents Chemother. 2019 05; 63(5).
    View in: PubMed
    Score: 0.133
  53. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 01; 39(1):10-39.
    View in: PubMed
    Score: 0.130
  54. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother. 2018 Apr; 30(2):115-119.
    View in: PubMed
    Score: 0.120
  55. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8).
    View in: PubMed
    Score: 0.118
  56. Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017 07; 61(7).
    View in: PubMed
    Score: 0.117
  57. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29.
    View in: PubMed
    Score: 0.109
  58. An institutional review of antimicrobial stewardship interventions. J Glob Antimicrob Resist. 2016 09; 6:75-77.
    View in: PubMed
    Score: 0.108
  59. Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2016 Feb; 60(2):1029-34.
    View in: PubMed
    Score: 0.105
  60. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. J Antimicrob Chemother. 2015 Mar; 70(3):877-81.
    View in: PubMed
    Score: 0.098
  61. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.
    View in: PubMed
    Score: 0.097
  62. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
    View in: PubMed
    Score: 0.082
  63. The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 01 10; 68(1):e0100923.
    View in: PubMed
    Score: 0.046
  64. A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
    View in: PubMed
    Score: 0.043
  65. Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Comput Methods Programs Biomed. 2022 Dec; 227:107212.
    View in: PubMed
    Score: 0.042
  66. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6).
    View in: PubMed
    Score: 0.029
  67. An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother. 2014 Mar; 20(3):224-7.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.